Previous Close | 26.32 |
Open | 26.25 |
Bid | 26.27 x 1800 |
Ask | 26.28 x 1300 |
Day's Range | 26.04 - 26.34 |
52 Week Range | 25.23 - 40.37 |
Volume | |
Avg. Volume | 42,576,651 |
Market Cap | 148.67B |
Beta (5Y Monthly) | 0.57 |
PE Ratio (TTM) | 70.96 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.68 (6.38%) |
Ex-Dividend Date | Jan 25, 2024 |
1y Target Est | N/A |
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.